



ASX/News Release

AVITA MEDICAL, INC. (ASX:AVH)

Results of Annual General Meeting

Valencia, Calif., USA, 4 June 2025 and Melbourne, Australia, 5 June 2025: In accordance with ASX Listing Rule 3.13.2, we advise the outcome in respect of each of the proposals put to the meeting of AVITA Medical, Inc.'s stockholders on June 4, 2025 (United States) / June 5, 2025 (Australia) in the attached voting results summary.

Authorized for release by the Chief Legal and Compliance Officer & Corporate Secretary of AVITA Medical, Inc.

ABOUT AVITA MEDICAL, INC.

AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute both Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm®, a biosynthetic wound matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact:

Jessica Ekeberg

Phone +1-661-904-9269

investor@avitamedical.com

media@avitamedical.com

###

AVITA Medical, Inc.
Annual Meeting of Shareholders
June 4, 2025 (United States) / June 5, 2025 (Australia)
Voting Results

The following information is provided for the purposes of ASX Listing Rule 3.13.2.

Proposal details	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll			Proposal result
Proposal	For	Against	Proxy's discretion	Abstain*	For	Against	Abstain*	Carried / not carried
Proposal 1: Election of Directors to serve a one-year term Louis Panaccio, Non-Executive Chairman of the Board of Directors	8,556,636 77.49%	0 0%	0 0%	2,484,940 22.51% (withheld)	8,556,636 77.49%	0 0%	2,484,940 22.51% (withheld)	Carried
Proposal 1: Election of Directors to serve a one-year term James Corbett, Executive Director and Chief Executive Officer	9,972,296 90.32%	0 0%	0 0%	1,069,273 9.68% (withheld)	9,972,296 90.32%	0 0%	1,069,273 9.68% (withheld)	Carried
Proposal 1: Election of Directors to serve a one-year term Professor Suzanne Crowe, Non-Executive Director	8,646,139 78.31%	0 0%	0 0%	2,395,437 21.69% (withheld)	8,646,139 78.31%	0 0%	2,395,437 21.69% (withheld)	Carried
Proposal 1: Election of Directors to serve a one-year term Jeremy Curnock Cook, Non-Executive Director	8,557,902 77.51%	0 0%	0 0%	2,483,674 22.49% (withheld)	8,557,902 77.51%	0 0%	2,483,674 22.49% (withheld)	Carried

<p>Proposal 1: Election of Directors to serve a one-year term</p> <p>Robert McNamara, Non-Executive Director</p>	<p>9,020,651 81.70%</p>	<p>0 0%</p>	<p>0 0%</p>	<p>2,020,925 18.30% (withheld)</p>	<p>9,020,651 81.70%</p>	<p>0 0%</p>	<p>2,020,925 18.30% (withheld)</p>	<p>Carried</p>
<p>Proposal 1: Election of Directors to serve a one-year term</p> <p>Jan Stern Reed, Non-Executive Director</p>	<p>8,816,188 79.85%</p>	<p>0 0%</p>	<p>0 0%</p>	<p>2,225,381 20.15% (withheld)</p>	<p>8,816,188 79.85%</p>	<p>0 0%</p>	<p>2,225,381 20.15% (withheld)</p>	<p>Carried</p>
<p>Proposal 1: Election of Directors to serve a one-year term</p> <p>Cary Vance, Non-Executive Director</p>	<p>9,011,807 81.62%</p>	<p>0 0%</p>	<p>0 0%</p>	<p>2,029,762 18.38% (withheld)</p>	<p>9,011,807 81.62%</p>	<p>0 0%</p>	<p>2,029,762 18.38% (withheld)</p>	<p>Carried</p>
<p>Proposal 2: To ratify the appointment of Grant Thornton LLP as the Company's independent public accountants for the fiscal year ending December 31, 2025</p>	<p>13,383,217 93.23%</p>	<p>604,414 4.21%</p>	<p>0 0%</p>	<p>367,110 2.56%</p>	<p>13,383,217 93.23%</p>	<p>604,414 4.21%</p>	<p>367,110 2.56%</p>	<p>Carried</p>
<p>Proposal 3: To approve the grant of 10,022 restricted stock units to acquire shares of the Company's common stock ("Common Stock") and the grant of 4,295 options to acquire shares of Common Stock to Lou Panaccio, pursuant to ASX Listing Rule 10.11</p>	<p>8,854,480 80.19%</p>	<p>1,871,636 16.95%</p>	<p>0 0%</p>	<p>315,511 2.86%</p>	<p>8,854,480 80.19%</p>	<p>1,871,636 16.95%</p>	<p>315,511 2.86%</p>	<p>Carried</p>
<p>Proposal 4: To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Prof. Suzanne Crowe, pursuant to ASX Listing Rule 10.11</p>	<p>8,832,786 80.00%</p>	<p>1,883,082 17.05%</p>	<p>0 0%</p>	<p>325,759 2.95%</p>	<p>8,832,786 80.00%</p>	<p>1,883,082 17.05%</p>	<p>325,759 2.95%</p>	<p>Carried</p>

Proposal 5: To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Jeremy Curnock Cook, pursuant to ASX Listing Rule 10.11	8,820,081 79.88%	1,888,090 17.10%	0 0%	333,456 3.02%	8,820,081 79.88%	1,888,090 17.10%	333,456 3.02%	Carried
Proposal 6: To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Robert McNamara, pursuant to ASX Listing Rule 10.11	8,833,929 80.01%	1,876,290 16.99%	0 0%	331,408 3.00%	8,833,929 80.01%	1,876,290 16.99%	331,408 3.00%	Carried
Proposal 7: To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Jan Stern Reed, pursuant to ASX Listing Rule 10.11	8,831,071 79.98%	1,879,952 17.03%	0 0%	330,604 2.99%	8,831,071 79.98%	1,879,952 17.03%	330,604 2.99%	Carried
Proposal 8: To approve the grant of 10,022 restricted stock units to acquire shares of Common Stock and the grant of 4,295 options to acquire shares of Common Stock to Cary Vance, pursuant to ASX Listing Rule 10.11	8,835,682 80.02%	1,875,897 16.99%	0 0%	330,048 2.99%	8,835,682 80.02%	1,875,897 16.99%	330,048 2.99%	Carried

<p>Proposal 9: To approve the grant of 520,000 options to acquire shares of Common Stock to the Company's Chief Executive Officer, James Corbett, pursuant to ASX Listing Rule 10.11</p>	<p>7,994,902 72.41%</p>	<p>2,772,833 25.11%</p>	<p>0 0%</p>	<p>273,892 2.48%</p>	<p>7,994,902 72.41%</p>	<p>2,772,833 25.11%</p>	<p>273,892 2.48%</p>	<p>Carried</p>
<p>Proposal 10: To approve, on an advisory basis, the compensation of our named executive officers</p>	<p>8,447,767 76.50%</p>	<p>2,221,096 20.12%</p>	<p>0 0%</p>	<p>372,764 3.38%</p>	<p>8,447,767 76.50%</p>	<p>2,221,096 20.12%</p>	<p>372,764 3.38%</p>	<p>Carried</p>
<p>Proposal 11: To approve (a) the 2020 Omnibus Incentive Plan Amended and Restated (the "Plan"); and (b) for purposes of ASX Listing Rule 7.2 Exception 13(b), which provides an exception to ASX Listing Rule 7.1, the issuance of the Company's equity securities under the Plan, for a period of up to three years from the date of stockholder approval in this FY25 annual shareholder meeting</p>	<p>6,876,570 62.27%</p>	<p>3,655,347 33.11%</p>	<p>0 0%</p>	<p>509,710 4.62%</p>	<p>6,876,570 62.27%</p>	<p>3,655,347 33.11%</p>	<p>509,710 4.62%</p>	<p>Carried</p>

*Votes relating to a person who abstained on Proposal 1 were not counted in determining whether or not the required majority of votes were cast for or against that Proposal. Votes relating to a person who abstained on Proposals 2, 3 - 8, 9, 10 or 11 (as applicable) were counted as votes "AGAINST" that Proposal in determining whether or not the required majority of votes were cast for or against that Proposal.